RAS/ERK modulates TGFβ-regulated PTEN expression in human pancreatic adenocarcinoma cells

Carcinogenesis

Volumn 28, Issue 11, 2007, Pages 2321-2327

  Chow, Jimmy Y C ^a   Quach, Khai T ^a   Cabrera, Betty L ^a   Cabral, Jennifer A ^a   Beck, Stayce E ^a   Carethers, John M ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ENZYME ANTIBODY; K RAS PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN ANTIBODY; SMAD2 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CARCINOMA CELL; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSOLIC FRACTION; DOWN REGULATION; ENZYME ACTIVATION; GENE MUTATION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PANCREAS CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE; FLAVONOIDS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 36148968456     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm159     Document Type: Article

References (42)

1. Warshaw,A.L. et al. (1992) Pancreatic carcinoma. N. Engl. J. Med., 326, 455-465.
2. Friess,H. et al. (1993) Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology, 105, 1846-1856.
3. Derynck,R. et al. (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet., 29, 117-129.
4. Pasche,B. (2001) Role of transforming growth factor beta in cancer. J. Cell. Physiol., 186, 153-168.
5. Roberts,A.B. et al. (2003) The two faces of transforming growth factor beta in carcinogenesis. Proc. Natl Acad. Sci. USA, 100 8621-8623.
6. Massague,J. (1996) TGFbeta signaling: Receptors, transducers, and Mad proteins. Cell, 85, 947-950.
7. Massague,J. et al. (2000) Transcriptional control by the TGF-beta/ Smad signaling system. EMBO J., 19, 1745-1754.
8. ten Dijke,P. et al. (2004) New insights into TGF-beta-Smad signalling. Trends Biochem. Sci., 29, 265-273.
9. Siegel,P.M. et al. (2003) Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl Acad. Sci. USA, 100, 8430-8435.
10. Gorska,A.E. et al. (2003) Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am. J. Pathol., 163, 1539-1549.
11. Bottinger,E.P. et al. (1997) Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas. EMBO J., 16, 2621-2633.
12. Li,W. et al. (2003) Squamous cell carcinoma and mammary abscess formation through squamous metaplasia in Smad4/Dpc4 conditional knockout mice. Development, 130, 6143-6153.
13. Takaku,K. et al. (1998) Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell, 92, 645-656.
14. Takaku,K. et al. (2002) No effects of Smad2 (madh2) null mutation on malignant progression of intestinal polyps in Apc(delta716) knockout mice. Cancer Res., 62, 4558-4561.
15. Amendt,C. et al. (1998) Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene, 17, 25-34.
16. Hahn,S.A. et al. (1996) Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res., 56, 490-494.
17. Hahn,S.A. et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science, 271, 350-353.
18. Carethers,J.M. et al. (2003) Neoplasia of the Gastrointestinal Tract In: Yamada,T., Alpers,D.H., Kaplowitz,N., Laine,L., Owyang,C., Powell,D.W. (eds): Textbook of Gastroenterology, 4th edition, Lippincott-Raven Publishers, Philadelphia, PA, pp. 557-583.
19. Laghi,L. et al. (2002) Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene, 21, 4301-4306.
20. Schwarz,L.C. et al. (1988) Loss of growth factor dependence and conversion of transforming growth factor-beta 1 inhibition to stimulation in metastatic H-ras-transformed routine fibroblasts. Cancer Res., 48, 6999-7003.
21. Filmus,J. et al. (1993) Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-beta during tumor progression. Curr. Opin. Oncol., 5, 123-129.
22. Kretzschmar,M. et al. (1999) A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes. Dev., 13, 804-816.
23. Li,J. et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275, 1943-1947.
24. Steck,P.A. et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet., 15, 356-362.
25. Maehama,T. et al. (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem., 273, 13375-13378.
26. Di Cristofano,A. et al. (2000) The multiple roles of PTEN in tumor suppression. Cell, 100, 387-390.
27. Simpson,L. et al. (2001) PTEN: Life as a tumor suppressor. Exp. Cell. Res., 264, 29-41.
28. Liaw,D. et al. (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet., 16, 64-67.
29. Marsh,D.J. et al. (1997) Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat. Genet., 16, 333-334.
30. Huang,S.C. et al. (2000) Genetic heterogeneity in familial juvenile polyposis. Cancer Res., 60, 6882-6885.
31. Carethers,J.M. (2005) Unwinding the heterogeneous nature of hamartomatous polyposis syndromes. JAMA, 294, 2498-2500.
32. Dong,J.T. et al. (1998) PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene, 17, 1979-1982.
33. Sakurada,A. et al. (1997) Infrequent genetic alterations of the PTEN/MMAC1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney, and ovary. Jpn. J. Cancer Res., 88, 1025-1028.
34. Li,D.M. et al. (1997) TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res., 57, 2124-2129.
35. Ebert,M.P. et al. (2002) Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br. J. Cancer, 86, 257-262.
36. Feig,L.A. et al. (1988) Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP. Mol. Cell. Biol., 8, 3235-3243.
37. Sano,T. et al. (1999) Differential expression of MMAC/PTEN in glioblastoma multiforme: Relationship to localization and prognosis. Cancer Res., 59, 1820-1824.
38. Hjelmeland,A.B. et al. (2005) Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. Cancer Res., 65 11276-11281.
39. Goel,A. et al. (2004) Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res., 64, 3014-3021.
40. Ijichi,H. et al. (2004) Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta. Oncogene, 23, 1043-1051.
41. Fink,S.R et al. (2003) TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene, 22 1317-1323.
42. Vazquez,F. et al. (2000) Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell. Biol., 20 5010-5018.